CYP2D6 genotype dependent oxycodone metabolism in postoperative patients

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Postoperative Pain Management

Background:

• The role of the polymorphic cytochrome P450 CYP2D6 enzyme in oxycodone metabolism and clinical efficacy is under investigation, with limited data in postoperative settings.
• This study hypothesizes that CYP2D6 genotype influences oxycodone plasma concentrations, its metabolites, and subsequent analgesic consumption.

Purpose of the Study:

• To investigate the impact of CYP2D6 genotype on oxycodone metabolism and analgesic requirements in the postoperative period.
• To determine the relationship between CYP2D6 activity and plasma concentrations of oxycodone and its metabolites.
• To assess genotype-dependent analgesic consumption and equianalgesic dosing.

Main Methods:

• 121 postoperative patients received oxycodone via patient-controlled analgesia (PCA).
• Plasma concentrations of oxycodone and metabolites (oxymorphone, noroxycodone, noroxymorphone) were analyzed using liquid chromatography-mass spectrometry.
• Patients were genotyped into poor (PM), intermediate (HZ/IM), extensive (EM), and ultrarapid (UM) metabolizer groups based on CYP2D6 activity.

Main Results:

• Significant differences in the oxymorphone/oxycodone plasma concentration ratio were observed across CYP2D6 genotypes (p = 0.005).
• Oxycodone consumption was highest in PMs within the first 12 hours, correlating with lower equianalgesic doses of piritramide (p < 0.001).
• No significant differences in pain scores were reported between genotypes.

Conclusions:

• The number of functional CYP2D6 alleles impacts oxycodone metabolism and analgesic consumption in the postoperative setting.
• Genotype-dependent variations in equianalgesic doses of piritramide to oxycodone were identified.
• Patient-controlled analgesia technology effectively managed the varying analgesic needs across different CYP2D6 genotypes.